Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alok Shetty

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
JCO Global Oncology|February 20, 2026
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AMLGojiri Mawalankar, Aarti Achrekar, Seema Biswas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based ChemoradiationVijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
Blood Advances|October 31, 2024
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortiumJessy Xinyi Han, Min Jung Koh, Leora Boussi, et al.
British Journal of Haematology|May 1, 2025
Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium studyMark N Sorial, Jessy Xinyi Han, Min Jung Koh, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
JCO Global Oncology|February 20, 2026
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AMLGojiri Mawalankar, Aarti Achrekar, Seema Biswas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based ChemoradiationVijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
Blood Advances|October 31, 2024
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortiumJessy Xinyi Han, Min Jung Koh, Leora Boussi, et al.
British Journal of Haematology|May 1, 2025
Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium studyMark N Sorial, Jessy Xinyi Han, Min Jung Koh, et al.
Pageof 2